Formoterol treatment downregulates the myostatin system in skeletal muscle of cachectic tumour-bearing rats

Oncology Letters

Volumn 3, Issue 1, 2012, Pages 185-189

  Busquets, Sílvia ^a   Toledo, Míriam ^a   Marmonti, Enrica ^a   Orpí, Marcel ^a   Capdevila, Eva ^a   Betancourt, Angelica ^a   López Soriano, Francisco J ^a   Argilés, Josep M ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Cachexia; Formoterol; Muscle wasting; Myostatin

Indexed keywords

FOLLISTATIN; FORMOTEROL; MESSENGER RNA; MYOSTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASCITES HEPATOMA; CACHEXIA; CONTROLLED STUDY; DOWN REGULATION; GASTROCNEMIUS MUSCLE; GENE EXPRESSION; MALE; MUSCLE ATROPHY; MUSCLE MASS; NONHUMAN; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 84855249313     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2011.442     Document Type: Article

References (50)

1. Harvey KB, Bothe A Jr and Blackburn GL: Nutritional assessment and patient outcome during oncological therapy. Cancer 43: 2065-2069, 1979.
2. Argiles JM, Alvarez B and Lopez-Soriano FJ: The metabolic basis of cancer cachexia. Med Res Rev 17: 477-498, 1997.
3. Argiles JM and Lopez-Soriano FJ: The ubiquitin-dependent proteolytic pathway in skeletal muscle: its role in pathological states. Trends Pharmacol Sci 17: 223-226, 1996.
4. Sanchis D, Busquets S, Alvarez B, Ricquier D, Lopez-Soriano FJ and Argiles JM: Skeletal muscle UCP2 and UCP3 gene expression in a rat cancer cachexia model. FEBS Lett 436: 415-418, 1998.
5. Van Royen M, Carbo N, Busquets S, et al: DNA fragmentation occurs in skeletal muscle during tumor growth: A link with cancer cachexia? Biochem Biophys Res Commun 270: 533-537, 2000.
6. Lee SJ and McPherron AC: Myostatin and the control of skeletal muscle mass. Curr Opin Genet Dev 9: 604-607, 1999.
7. Sharma M, Langley B, Bass J and Kambadur R: Myostatin in muscle growth and repair. Exerc Sport Sci Rev 29: 155-158, 2001.
8. Tsuchida K: Targeting myostatin for therapies against muscle-wasting disorders. Curr Opin Drug Discov Devel 11: 487-494, 2008.
9. McPherron AC, Lawler AM and Lee SJ: Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 387: 83-90, 1997.
10. Elkasrawy MN and Hamrick MW: Myostatin (GDF-8) as a key factor linking muscle mass and bone structure. J Musculoskelet Neuronal Interact 10: 56-63, 2010.
11. Lee SJ: Sprinting without myostatin: a genetic determinant of athletic prowess. Trends Genet 23: 475-477, 2007.
12. Lee SJ: Regulation of muscle mass by myostatin. Annu Rev Cell Dev Biol 20: 61-86, 2004.
13. Anderson SB, Goldberg AL and Whitman M: Identification of a novel pool of extracellular pro-myostatin in skeletal muscle. J Biol Chem 283: 7027-7035, 2008.
14. Hill JJ, Davies MV, Pearson AA, et al: The myostatin propeptide and the follistatin-related gene are inhibitory binding proteins of myostatin in normal serum. J Biol Chem 277: 40735-40741, 2002.
15. Guo T, Jou W, Chanturiya T, Portas J, Gavrilova O and McPherron AC: Myostatin inhibition in muscle, but not adipose tissue, decreases fat mass and improves insulin sensitivity. PLoS One 4: e4937, 2009.
16. Wolfman NM, McPherron AC, Pappano WN, et al: Activation of latent myostatin by the BMP-1/tolloid family of metalloproteinases. Proc Natl Acad Sci USA 100: 15842-15846, 2003.
17. Lee SJ: Genetic analysis of the role of proteolysis in the activation of latent myostatin. PLoS One 3: e1628, 2008.
18. De Caestecker M: The transforming growth factor-beta superfamily of receptors. Cytokine Growth Factor Rev 15: 1-11, 2004.
19. Rodino-Klapac LR, Haidet AM, Kota J, Handy C, Kaspar BK and Mendell JR: Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease. Muscle Nerve 39: 283-296, 2009.
20. Allendorph GP, Vale WW and Choe S: Structure of the ternary signaling complex of a TGF-beta superfamily member. Proc Natl Acad Sci USA 103: 7643-7648, 2006.
21. Steelman CA, Recknor JC, Nettleton D and Reecy JM: Transcriptional profiling of myostatin-knockout mice implicates Wnt signaling in postnatal skeletal muscle growth and hypertrophy. FASEB J 20: 580-582, 2006.
22. Joulia-Ekaza D and Cabello G: The myostatin gene: physiology and pharmacological relevance. Curr Opin Pharmacol 7: 310-315, 2007.
23. Whittemore LA, Song K, Li X, et al: Inhibition of myostatin in adult mice increases skeletal muscle mass and strength. Biochem Biophys Res Commun 300: 965-971, 2003.
24. Durieux AC, Amirouche A, Banzet S, et al: Ectopic expression of myostatin induces atrophy of adult skeletal muscle by decreasing muscle gene expression. Endocrinology 148: 3140-3147, 2007.
25. McFarlane C, Plummer E, Thomas M, et al: Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF-κB-independent, FoxO1-dependent mechanism. J Cell Physiol 209: 501-514, 2006.
26. Stock MJ and Rothwell NJ: Effects of β-adrenergic agonists on metabolism and body composition. In: Control and manipulation of Animal Growth. Buttery PJ, Hayes NB and Lindsay DB (eds.). Butterworths, London, pp 249-257, 1985.
27. Kim YS and Sainz RD: Beta-adrenergic agonists and hypertrophy of skeletal muscles. Life Sci 50: 397-407, 1992.
28. Agbenyega ET and Wareham AC: Effect of clenbuterol on skeletal muscle atrophy in mice induced by the glucocorticoid dexamethasone. Comp Biochem Physiol Comp Physiol 102: 141-145, 1992.
29. Rajab P, Fox J, Riaz S, Tomlinson D, Ball D and Greenhaff PL: Skeletal muscle myosin heavy chain isoforms and energy metabolism after clenbuterol treatment in the rat. Am J Physiol Regul Integr Comp Physiol 279: R1076-R1081, 2000.
30. Hinkle RT, Hodge KM, Cody DB, Sheldon RJ, Kobilka BK and Isfort RJ: Skeletal muscle hypertrophy and anti-atrophy effects of clenbuterol are mediated by the beta2-adrenergic receptor. Muscle Nerve 25: 729-734, 2002.
31. Wineski LE, von Deutsch DA, Abukhalaf IK, Pitts SA, Potter DE and Paulsen DF: Muscle-specific effects of hindlimb suspension and clenbuterol in mature male rats. Cells Tissues Organs 171: 188-198, 2002.
32. Busquets S, Figueras MT, Fuster G, et al: Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting. Cancer Res 64: 6725-6731, 2004.
33. Tessitore L, Costelli P, Bonetti G and Baccino FM: Cancer cachexia, malnutrition, and tissue protein turnover in experimental animals. Arch Biochem Biophys 306: 52-58, 1993.
34. Chomczynski P and Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159, 1987.
35. Gonzalez-Cadavid NF, Taylor WE, Yarasheski K, et al: Organization of the human myostatin gene and expression in healthy men and HIV-infected men with muscle wasting. Proc Natl Acad Sci USA 95: 14938-14943, 1998.
36. Costelli P, Muscaritoli M, Bonetto A, et al: Muscle myostatin signalling is enhanced in experimental cancer cachexia. Eur J Clin Invest 38: 531-538, 2008.
37. Joulia-Ekaza D and Cabello G: Myostatin regulation of muscle development: molecular basis, natural mutations, physiopathological aspects. Exp Cell Res 312: 2401-2414, 2006.
38. Kollias HD and McDermott JC: Transforming growth factor-beta and myostatin signaling in skeletal muscle. J Appl Physiol 104: 579-587, 2008.
39. Shimasaki S, Koga M, Esch F, et al: Primary structure of the human follistatin precursor and its genomic organization. Proc Natl Acad Sci USA 85: 4218-4222, 1988.
40. Aoki MS, Soares AG, Miyabara EH, Baptista IL and Moriscot AS: Expression of genes related to myostatin signaling during rat skeletal muscle longitudinal growth. Muscle Nerve 40: 992-999, 2009.
41. Ouchi N, Oshima Y, Ohashi K, et al: Follistatin-like 1, a secreted muscle protein, promotes endothelial cell function and revascularization in ischemic tissue through a nitric-oxide synthase-dependent mechanism. J Biol Chem 283: 32802-32811, 2008.
42. Cowling BS, McGrath MJ, Nguyen MA, et al: Identification of FHL1 as a regulator of skeletal muscle mass: implications for human myopathy. J Cell Biol 183: 1033-1048, 2008.
43. Zamora E, Lupon J, Simo R and Galan A: Myostatin serum levels in heart failure. Eur J Heart Fail 12: 1379; author reply 1379-1380, 2010.
44. Llovera M, Carbo N, Lopez-Soriano J, et al: Different cytokines modulate ubiquitin gene expression in rat skeletal muscle. Cancer Lett 133: 83-87, 1998.
45. Llovera M, Garcia-Martinez C, Agell N, et al: Ubiquitin and proteasome gene expression is increased in skeletal muscle of slim AIDS patients. Int J Mol Med 2: 69-73, 1998.
46. Llovera M, Garcia-Martinez C, Lopez-Soriano J, et al: Role of TNF receptor 1 in protein turnover during cancer cachexia using gene knockout mice. Mol Cell Endocrinol 142: 183-189, 1998.
47. Llovera M, Garcia-Martinez C, Agell N, Lopez-Soriano FJ and Argiles JM: Muscle wasting associated with cancer cachexia is linked to an important activation of the ATP-dependent ubiquitin-mediated proteolysis. Int J Cancer 61: 138-141, 1995.
48. Garcia-Martinez C, Llovera M, Agell N, Lopez-Soriano FJ and Argiles JM: Ubiquitin gene expression in skeletal muscle is increased by tumour necrosis factor-alpha. Biochem Biophys Res Commun 201: 682-686, 1994.
49. Llovera M, Garcia-Martinez C, Agell N, Marzabal M, Lopez-Soriano FJ and Argiles JM: Ubiquitin gene expression is increased in skeletal muscle of tumour-bearing rats. FEBS Lett 338: 311-318, 1994.
50. Schneyer A, Tortoriello D, Sidis Y, Keutmann H, Matsuzaki T and Holmes W: Follistatin-related protein (FSRP): a new member of the follistatin gene family. Mol Cell Endocrinol 180: 33-38, 2001.